Why Johnson & Johnson’s new ETHICON 4000 stapler could matter for European surgical workflow economics
Read how Johnson & Johnson’s ETHICON 4000 CE Mark approval could reshape surgical stapling, hospital economics, and future robotic integration.
Why Johnson & Johnson’s May 19 RBC fireside chat matters more than it first appears
Johnson & Johnson will join RBC Healthcare 2026 on May 19. Read why investors will watch the fireside chat for growth, guidance, and risk signals.
Can TECNIS PureSee help Johnson & Johnson win the next phase of premium cataract surgery?
Johnson & Johnson’s TECNIS PureSee data could reshape premium cataract surgery. Read what the ASCRS 2026 findings may change next.
Johnson & Johnson expands pulsed field ablation footprint as VARIPULSE reaches Peru electrophysiology centers
Johnson & Johnson launches VARIPULSE pulsed field ablation technology in Peru. Discover what this means for atrial fibrillation treatment and electrophysiology innovation.
Johnson & Johnson’s TECNIS PureSee approval highlights the evolving battle between EDOF and multifocal cataract lenses
Johnson & Johnson wins FDA approval for TECNIS PureSee IOL. Discover what this extended depth of focus cataract lens means for surgeons and patients.
Johnson & Johnson strengthens its multiple myeloma franchise with TECVAYLI and DARZALEX FASPRO approval. What clinicians are watching next
FDA approves TECVAYLI plus DARZALEX FASPRO for relapsed multiple myeloma. Discover what the MajesTEC-3 data means for future immunotherapy strategies.
J&J’s Tecvayli-Darzalex Faspro combination approved for myeloma after MajesTEC-3 Phase 3 results
FDA approves J&J’s teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.
Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care
Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.
Johnson & Johnson’s early OMNYPULSE data show promise, but the real test lies ahead
Johnson & Johnson has presented 12-month pilot data from the OMNY-AF study evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation at the 2026 AF Symposium. The early pilot cohort reported high acute procedural success, no procedure-related adverse events, and a 12-month freedom from atrial fibrillation rate approaching 90 percent. The […]
What Johnson & Johnson’s AKEEGA opinion means for PARP inhibitors beyond castration resistance
Find out how Johnson & Johnson’s CHMP opinion for AKEEGA could shift prostate cancer treatment toward earlier, biomarker-guided precision therapy.